Literature DB >> 12630825

Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension.

Noritoshi Nagaya1, Kunio Miyatake, Shingo Kyotani, Toshio Nishikimi, Norifumi Nakanishi, Kenji Kangawa.   

Abstract

This study sought to investigate pulmonary vasodilator responses to intrapulmonary and intravenous infusion of adrenomedullin (AM) in patients with pulmonary hypertension. In 10 patients with pulmonary hypertension, blood flow velocity in a segmental pulmonary artery was measured using a Doppler flow wire during intrapulmonary infusion of AM, acetylcholine (ACh), and adenosine triphosphate (ATP). The hemodynamic effects of intravenously administered AM (0.05 microg/kg/min) were examined in another 5 patients with primary pulmonary hypertension. Intrapulmonary infusion of AM, ACh or ATP caused a significant dose-dependent increase in blood flow velocity in a segmental pulmonary artery, respectively. The increase in flow velocity with AM at 10(-8) mol/l (41 +/- 6% of the baseline value) was comparable to that with ACh at 10(-4) mol/l (39 +/- 11%) and that with ATP at 10(-5) mol/l (36 +/- 14%), suggesting a strong pulmonary vasodilator activity of AM. Intravenous infusion of AM produced a 41% increase in cardiac index (p < 0.05) and a 30% decrease in pulmonary vascular resistance (p < 0.05) with a 3% reduction in mean pulmonary arterial pressure (p = NS). These results suggest that, on a molar basis, AM may have much more potent pulmonary vasodilator activity than ACh and ATP, and thus may have beneficial hemodynamic effects in patients with pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12630825     DOI: 10.1291/hypres.26.s141

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  3 in total

Review 1.  Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target.

Authors:  Reza Aghamohammadzadeh; Sarah Withers; Fiona Lynch; Adam Greenstein; R Malik; Anthony Heagerty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 2.  Drug treatment of pulmonary arterial hypertension: current and future agents.

Authors:  Marius M Hoeper
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Proteomic profiling identifies key differences between inter-stage infants with single ventricle heart disease and healthy controls.

Authors:  Benjamin S Frank; Ludmila Khailova; Lori Silveira; Max B Mitchell; Gareth J Morgan; Elena W Y Hsieh; Michael V DiMaria; Mark Twite; Jelena Klawitter; Jesse A Davidson
Journal:  Transl Res       Date:  2020-10-09       Impact factor: 7.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.